Printer Friendly

N.Wales at forefront of blood-clot battle; St Asaph firm's PS2m aid for revolutionary test kit.


A NEW home-testing device that will allow patients taking anti-coagulant drugs to check their own blood will soon be on the market thanks to a PS2m investment.

The device has been designed by St Asaph-based company, Microvisk, for patients who take blood thinning drugs such as Warfarin to prevent life-threatening blood clots.

Using the device, patients can take a tiny blood sample and test its coagulation properties.

Results can be sent by phone or online to the doctor and will help avoid regular trips to the GP surgery or hospital, and provide instant feedback about whether their drug dosage needs to be adjusted.

The device is the first application of a platform Work at technology, developed by Microvisk, that can measure fluid viscosity on a micro scale.

The technology could also be used to perform other less routine blood coagulation tests that currently would have to be performed in a laboratory.

The versatility of the technology and the simplicity of the device have made Microvisk attractive to investors who believe St Asaph the company has the potential to revolutionise home testing. Porton Capital, which first invested in the company five years ago, has led the most recent investment round, which includes other existing funds, Oxford Technology Fund, Advantage Growth Fund and several private investors to provide the company with a further PS2m.

The cash boost will enable the company to complete the design of the unit and strip so before it is submitted for regulatory approval at the end of this year.

Bill Moffitt, chairman of Microvisk, said: "Porton Capital has been one of the loyal supporters of the company almost from inception.

"This new investment round allows us to finish off our design work and we can then move into a short phase of clinical trials which will lead to regulatory approval both in Europe and North America.

"The investment will also give us the means to look at other blood coagulation tests that the Microvisk device can perform" Harvey Boulter, CEO of the Porton Group, said: "We are delighted to make a further investment in Microvisk.

"It is developing a product which addresses a global need - nearly everyone I speak to knows someone who has had a stroke or a heart problem and has therefore been prescribed anti-coagulants. "They are cheap yet reliable if regularly checked.

"We recognised the potential of Microvisk at an early stage and I am pleased that we have been able to provide funds to keep the momentum going and the exciting challenge of product launch is now only a matter of months away.


Work at Microvisk, St Asaph
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Daily Post (Conwy, Wales)
Date:May 30, 2013
Previous Article:Medieval times return to Mold.
Next Article:Housing standards on track for 2020.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters